Kodiak Sciences(NASDAQ) KOD

Kodiak Sciences creates new medicines to treat common causes of blindness. These treatments help people suffering from serious retinal eye diseases. They use molecular engineering to make longer-lasting eye injections.

Fighting Vision Loss

• Zenkuda (tarcocimab): An investigational eye injection designed to treat high-prevalence diseases like wet age-related macular degeneration and diabetic retinopathy.
• KSI-501: A bispecific therapy that targets two different proteins to improve treatment durability for retinal vascular diseases.
• KSI-101: A high-strength protein therapy for patients with macular edema, which is fluid in the retina caused by inflammation.
• ABC Platform: A molecular engineering technology that combines proteins with chemical polymers to create medicines that stay in the eye longer.

Building a Pipeline

• Formed a manufacturing partnership with Lonza to build a custom facility for producing antibody biopolymer conjugates at commercial scale.
• Resumed development of tarcocimab in November 2023 after reviewing data from clinical studies in diabetic retinopathy and retinal vein occlusion.
• Expanded technology into the ABCD category to include small molecule drugs for treating glaucoma and geographic atrophy.
• Developed the VETi program, which uses artificial intelligence and wearable headsets to improve retina care and identity security.

Engineering Durability

Kodiak uses its proprietary ABC Platform to merge protein-based and chemistry-based therapies into single molecules. This molecular engineering aims to reduce how often patients need eye injections by extending the time medicine remains active in the eye.

Tracking the Numbers

• Net loss reached $58.2 million in Q1 2026, a 1.2% deepening compared to the $57.5 million loss in Q1 2025.
• Operating expenses hit $59.8 million for the three months ended March 31, 2026, increasing 1.2% year-over-year.
• Research and development costs rose to $48.5 million in Q1 2026, up 11.2% from $43.6 million in the prior year period.
• Cash and cash equivalents totaled $169.5 million as of March 31, 2026, down from $209.9 million at the end of 2025.
• Market capitalization grew to $2.4 billion in Q1 2026, representing a 1491% increase from $148.2 million in Q1 2025.

The Road Ahead

Kodiak has transitioned from an early research firm into a late-stage clinical developer focused on multi-specific eye therapies. While the company faces significant financial losses and funding needs, it continues to advance a diverse portfolio of investigational retinal medicines.